Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.

UNLABELLED: Two mitogen-activated protein kinase kinase (MAPK2, also known as MEK) inhibitors were assessed with (18)F-FDG PET in separate phase I clinical studies, clearly illustrating the potential of metabolic imaging for dose, dosing regimen, and compound selection in early-phase trials and uti...

ver descrição completa

Detalhes bibliográficos
Principais autores: Kraeber-Bodéré, F, Carlier, T, Naegelen, V, Shochat, E, Lumbroso, J, Trampal, C, Nagarajah, J, Chua, S, Hugonnet, F, Stokkel, M, Gleeson, F, Tessier, J
Formato: Journal article
Idioma:English
Publicado em: 2012